Guard Therapeutics: Phase IIb study POINTER ends in failure - Redeye

Redeye comments on the disappointing news that Guard Therapeutics' drug candidate RMC-035 did not meet its endpoints in its phase IIb study POINTER. We anticipate a share price decline of 80-90% today.

Länk till analysen i sin helhet: https://www.redeye.se/research/1133621/guard-therapeutics-phase-iib-study-pointer-ends-in-failure?utm_source=finwire&utm_medium=RSS